Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

fically inhibit the production of VLA-4 could significantly reduce disease activity in RRMS patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 is very promising particularly when considering the short duration of dosing within the trial. As an antisense drug ATL/TV1102 will have a different, potentially preferable, safety profile to other drugs that target VLA-4 and therefore presents an exciting future treatment option for RRMS patients."

Mark Diamond, Chief Executive Officer of Antisense Therapeutics, said, "We are delighted to have our ATL/TV1102 Phase IIa trial results presented at such an important scientific meeting on MS. The development of ATL/TV1102 as an MS treatment continues with our partner Teva Pharmaceutical Industries (Teva) and we look forward to the prospect of Teva reporting on ATL/TV1102's future clinical progress. Importantly, the demonstration of significant disease activity with ATL/TV1102 in MS points to the potential of ATL/TV1102 in other disease settings such as autoimmune, inflammation and cancer. It also provides important validation for the application of second-generation antisense drugs outside of cardiovascular and metabolic diseases such as high cholesterol and diabetes where there has been success to date. We believe our results provide important substantiation for the broader clinical application of the second-generation technology."

"We are very encouraged by the data. Not only do they represent promising results for patients with MS, but they also evidence the significant progress we are making in demonstrating the effectiveness, efficiency and the breadth of opportunity of our antisense platform. It's another disease and another tissue where we have great proof-of-concept for antisense drugs," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship with Teva to move the drug forward further validates our business strategy.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester ... – Trends & Forecast to 2018," defines and segments ... volume and value. The report also estimates the demand ... phthalic anhydride is projected to grow from an estimated ... with a CAGR of 5.24% from 2013 to 2018. ...
(Date:7/12/2014)... 12, 2014 The Security Analytics market ... to $3,376.6 million by 2019, at an expected CAGR ... The challenges to counter the increasing number of security ... outdated cyber defense systems in organizations are enormous. Vendors ... remodeling their existing architecture to develop better and more ...
(Date:7/12/2014)... increase in the summer as people gather around fire pits, ... vulnerable to these seasonal fire hazards: children. "Young children ... putting their hands on the side of cooking grills," Dr. ... University Medical Center in Maywood, Ill., said in a Loyola ... with fire, you get burned, is true -- you ...
(Date:7/12/2014)... As DePuy Pinnacle hip lawsuits ( ... Bernstein Liebhard LLP notes the publication of a new ... failure of metal-on-metal hip replacements. The research, which appears ... Bone & Joint Surgery, looked at 597 patients ... at least twelve months earlier. The blood metal ion ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... half a million women around the world, including an ... planning methods developed by Georgetown University Medical Centers Institute ... of others use CycleBeads a visual aid developed by ... plan or prevent pregnancy. , Now CycleBeads are ...
... model of Treacher Collins Syndrome (TCS), the Stowers Institutes Trainor ... of craniofacial development either by inactivating a gene implicated in ... The work, which was posted to the Web site of ... teams 2006 discovery of the cellular cause of TCS. ...
... Higher Protein, Fish-based Formula Ideal for Dogs ... The Wellness(R),( http://www.wellnesspetfood.com ) brand of ... the availability of Wellness CORE(TM) Dog Ocean ... CORE Dog line. CORE Ocean delivers a,fish- ...
... Mercury has again been in,the news with the ... sushi by,the New York Times and Oceana/Mercury Policy Project ... 3 pieces of tuna tested had levels,above FDA,s action ... interests,against those covering the news was swift and erroneous. ...
... Company, Inc. (Nasdaq: IPCM ), a leading provider of ... and,Jeffrey Taylor, President and Chief Operating Officer, are scheduled to,present ... Services,Conference in New York, NY., Event: 2008 ... February 11, 2008 Time: 9:00 a.m. ET ...
... it has been common practice to exclude older patients from ... rates. , However, patients such as ... are proving that perhaps age does not always matter. ... that select patients age 65 and older can safely undergo ...
Cached Medicine News:Health News:CycleBeads help women manage their fertility 2Health News:Trainor Lab prevents rare birth defect by inactivating p53 gene 2Health News:Introducing New Wellness(R) CORE(TM) Dog Ocean Formula - The Most Balanced Fish-Based Grain-Free Diet Available 2Health News:Introducing New Wellness(R) CORE(TM) Dog Ocean Formula - The Most Balanced Fish-Based Grain-Free Diet Available 3Health News:Introducing New Wellness(R) CORE(TM) Dog Ocean Formula - The Most Balanced Fish-Based Grain-Free Diet Available 4Health News:Global Consensus on Mercury: Scientists Defend Science Journalists 2Health News:Global Consensus on Mercury: Scientists Defend Science Journalists 3Health News:Global Consensus on Mercury: Scientists Defend Science Journalists 4Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Study finds good outcomes for older lung transplant patients 2
All metal for storing 5 cm x 5 cm (2 inches x 2 inches) 35 mm color slides. Each is individually crafted of high grade steel and finished with a durable baked enamel finish....
Individually, self-contained, stackable drawers....
Shandon Wooden Slide File Storage Box...
Modular Specimen Filing System has five cells that can hold either slides or tissue cassettes....
Medicine Products: